However, given that these cancers develop chemotherapy resistance within a few months after initial treatment, we predicted that SLFN11—a biomarker of cisplatin and PARP inhibitor response—may be downregulated following platinum-based chemotherapy. This evidence concerns the gene PARP1 and cancer.